First Manhattan
NBRV

First Manhattan’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

First Manhattan’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$6K – 1453
2020
Q3 		$6K Hold
50
– – ﹤0.01% 1186
2020
Q2 		$8K Hold
50
– – ﹤0.01% 1201
2020
Q1 		$7K Buy
+50
New +$15.3K ﹤0.01% 1203

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

First Manhattan's NBRV Position: Q4 2020 in Review

First Manhattan sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 50 shares — an estimated $6K sold.

First Manhattan first reported a position in NBRV in Q1 2020 and held it in 3 quarters. The position peaked at $8K in Q2 2020. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • First Manhattan reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • First Manhattan sold 50 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $6K.
  • First Manhattan first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2020 and held it in 3 quarters.
  • First Manhattan's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $8K in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on First Manhattan's 13F filing for Q4 2020, filed 16 Feb 2021.